Sunshine Biopharma, Inc.
NASDAQ: SBFM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Steve N. Slilaty
- Employees
- 52
- Headquarters
- Pointe-Claire, Canada
- IPO year
- 2022
- Market cap
- $1.0M
- Website
- https://www.sunshinebiopharma.com
Loading SBFM…
Loading profile data…Frequently asked questions about SBFM
What does Sunshine Biopharma, Inc. (SBFM) do?
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of maligna...
Where does SBFM trade?
Sunshine Biopharma, Inc. (SBFM) trades on the NASDAQ Capital Market.
What sector is SBFM in?
Sunshine Biopharma, Inc. (SBFM) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Sunshine Biopharma, Inc.?
Steve N. Slilaty is the chief executive officer of Sunshine Biopharma, Inc. (SBFM).
Where is Sunshine Biopharma, Inc. headquartered?
Sunshine Biopharma, Inc. is headquartered in Canada.
Does SBFM pay a dividend?
Sunshine Biopharma, Inc. (SBFM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SBFM go public?
Sunshine Biopharma, Inc. (SBFM) completed its initial public offering in 2022.